Introduction
============

Tuberculosis (TB) is a preventable and curable infectious disease, and yet it remains a significant global public health challenge. Each year, tuberculosis infects millions of people and it is the second leading cause of death by infectious diseases worldwide \[[@b1-cm-88-164]\]. A better understanding of the host immune response against M. tuberculosis is crucial to elucidate this fatal disease. Several studies have shown that when tuberculosis infection occurs, a variety of pro and anti-inflammatory cytokines are produced at disease sites and then released into circulation \[[@b2-cm-88-164],[@b3-cm-88-164]\]. Interleukin-10 (IL-10) is one of the most important anti-inflammatory cytokine reported to affect multiple cell types, including macrophages, monocytes, dendritic cells, CD4 T cells and CD8 T cells \[[@b4-cm-88-164]\]. The dominant function of IL-10 is to down-regulate the immune response and limit tissue injury. However, the excessive production of this cytokine directly inhibits CD4+ T cell responses which may result in a failure to control the infection \[[@b5-cm-88-164]\].

The main objective of this study was to investigate the levels of IL-10 in plasma of patients with different clinical manifestations of tuberculosis and to evaluate the possible effects of treatment on these levels.

Material and methods
====================

Study subjects
--------------

The study was conducted at "Leon Daniello" Pneumology Hospital in Cluj Napoca, Romania. Twenty eight patients with active pulmonary TB attending the hospital were included. Study participants were evaluated by medical history, physical examination, chest X-ray, sputum acid-fast bacilli smear, mycobacterial culture and drug susceptibility testing. Patients with human immunodeficiency virus and diabetes mellitus were excluded. A control group of 21 healthy individuals (with no history of TB and no evidence of disease by clinical examination) were recruited. The protocol for this study was approved by the Ethics Committee of Iuliu Hatieganu University of Medicine and written informed consent was signed by each patient.

Blood sampling
--------------

Venous blood samples were collected from patients before starting anti-tuberculosis treatment (ATT), after 3 months of ATT and after 6 months of ATT. Blood samples were directly centrifuged at 1000 × g for 15 minutes and then plasma were collected and stored at −20 °C until use.

Measurement of IL-10 cytokine levels
------------------------------------

The plasma levels of IL-10 were quantified using a sandwich enzyme immunoassay kit according to the manufacturer's protocol (R&D Systems, Inc., Minneapolis, U.S.A.). The minimum detectable dose of IL-10 was typically less than 3.9 pg/mL.

Statistical analyses
--------------------

All data were analyzed using GraphPad Prism version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Differences in cytokine levels among groups were evaluated by the Kruskal-Wallis and Mann-Whitney U tests. A p-value of \<0.05 was considered statistically significant.

Results
=======

There were no statistically significant age or gender differences among the groups. Body temperature at admission was significantly higher in TB patients than in healthy individuals. Of 30 TB patients enrolled in the study, 22 cases had positive smears for AFB and 8 cases had negative smears. The results showed that the levels of IL-10 were higher in TB patients compared to healthy subjects ([Fig. 1](#f1-cm-88-164){ref-type="fig"}). The clinical severity of pulmonary TB in patients was determined on the basis of chest radiography results. Patients with abnormal chest X-Ray findings had higher IL-10 levels when compared to patients with normal X-Rays ([Fig. 2](#f2-cm-88-164){ref-type="fig"}).

In our study, a subgroup of 18 patients was followed during and after anti-tuberculous therapy. The mean IL-10 level in TB patients before ATT was higher than in patients during therapy and in patients after treatment ([Fig. 3](#f3-cm-88-164){ref-type="fig"}).

Discussion
==========

Interleukin-10 is one of the most important anti-inflammatory cytokine reported to inhibit CD4+ T cell responses by inhibiting APC function of cells infected with mycobacteria \[[@b6-cm-88-164]\]. To evaluate the association of IL-10 cytokine with various disease stages of TB, plasma levels of IL-10 were measured in active TB patients before treatment, after three months of treatment and at the end of treatment.

The results showed that the levels of IL-10 were significantly higher in TB patients compared to healthy subjects (p\<0.05). After determining the clinical severity of TB in patients on the basis of chest radiography results, we observed that patients with abnormal chest X-Ray findings had higher IL-10 levels when compared to patients with normal X-Rays (p=0.03).

Our findings are similar with previous studies that have shown higher levels of IL-10 in the active TB group than in the control group, reporting even a correlation between IL-10 and susceptibility for TB \[[@b7-cm-88-164],[@b8-cm-88-164],[@b9-cm-88-164]\]. IL-10 can be found in the serum, plasma and bronchoalveolar lavage fluid of active TB patients and may contribute to the anergy and failure of lymphocytes to proliferate in response to Mtb \[[@b10-cm-88-164],[@b11-cm-88-164]\]. It is the balance between the inflammatory and protective immune response that determines the outcome of tuberculosis infection \[[@b5-cm-88-164]\].

In our study, the possible effect of treatment on plasma IL-10 levels in TB patients was evaluated. All the patients included in the study received the first standard antituberculous treatment under direct observed treatment strategy which consisted of isoniazid, rifampin, pyrazinamide and ethambutol (2HRZE/4HR) according to the national TB program. To our knowledge, this is the first study to evaluate the effects of antituberculous treatment on plasma IL-10 levels in Romanian TB patients. IL-10 levels were determined in 18 patients after three months of treatment and at the end of treatment. We observed a statistically significant decreasing of IL-10 level during treatment. The mean IL-10 level in patients with active TB was higher than in patients during therapy (P not significant) and in patients after treatment (P\<0.01).

Another study has recently shown a consistent decrease in IL-10 levels in active TB patients at all-time points of therapy, suggesting that patients who maintain high IL-10 levels at the end of treatment are exposed to TB recurrence \[[@b12-cm-88-164]\]. Sahiratmadja et al. also observed reduced IL-10 production during TB therapy, suggesting that this cytokine may be a useful biomarker signature to assess the disease progression \[[@b13-cm-88-164]\]. Studies on peripheral blood mononuclear cells obtained from TB patients have shown that neutralization of endogenous IL-10 increased T-cell proliferation and IFN- production \[[@b14-cm-88-164],[@b15-cm-88-164]\]. Collectively, these studies concluded that IL-10 was functioning to limit the immune response to Mtb and may contribute to TB pathogenesis \[[@b15-cm-88-164],[@b16-cm-88-164]\].

Previous studies suggest that in tuberculosis, over expressed IL-10 during the chronic phase of the infection showed evidence of reactivation of tuberculosis with a highly significant increase in bacterial numbers within the lungs. This reactivation was shown to be associated with the formation of macrophage-dominated lesions. In addition, IL-10 plays a pivotal role during the chronic/latent stage of pulmonary tuberculosis, with increased production playing a potentially central role in promoting reactivation tuberculosis \[[@b17-cm-88-164]\].

In the present study, no significant association was found regarding the plasma level of IL-10 and BCG vaccination, positive smear or weight lost (data not shown).

The limitation of the current study is that the specific cellular source of IL-10 in plasma of our patients has not been assessed. Further studies are necessary to identify the exact source of IL-10 in response to Mtb infection and to see if it could be used in the follow-up as a clinical biomarker of disease progression.
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